Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug shows promise for healing hearts after attack

NCT ID NCT07169981

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at whether the diabetes drug empagliflozin (Jardiance) can help repair heart damage in diabetic patients who had a major heart attack. 200 participants took either 10 mg or 25 mg of the drug daily for 6 months. Researchers measured changes in heart size, pumping strength, and overall function to see if the drug improves heart remodeling.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
empagliflozin (Jardiance)
What this could lead to
If successful, this could show that empagliflozin helps repair heart damage after a heart attack in diabetic patients, potentially improving heart function and reducing future heart problems.
What could go wrong
This is a small, completed Phase 2 trial, so results are preliminary. The benefits seen may not be large or may not apply to all patients. The drug is already approved for diabetes and heart failure, so major new risks are unlikely, but side effects like dehydration or urinary infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

200 people

The number who actually took part.

Started

Jul 2023

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Diabetic patients with anterior STEMI with reduced LVEF who underwent PPCI with successful revascularization and resulting into TIMI III flow and who are receiving SGLTi for the first time. Exclusion Criteria: 1. patients who did not undergo primary PCI, those treated medically or had thrombolysis 2. Non diabetic patient. 3. Diabetic patient already on SGLTi 4. STEMIs other than anterior. 5. NSTEMI patients. 6. Patients having valvular heart diseases. 7. Patients having renal impairment. 8. Patients with LV myopathies of non-ischemic origin.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anterior ST-elevation myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus heart failure ST-elevation myocardial infarction systolic heart failure type 2 diabetes mellitus Ventricular Remodeling

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabete mellitus Heart failure Remodeling, left ventricle

Contacts and locations

Locations

  • Ain Shams University Hospitals

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.